MMR Information Systems, Inc., a provider of secure and easy-to-use online personal health records and electronic safe deposit box storage solutions, recently announced that the company has entered into an agreement with sanofi-aventis China regarding MMR’s anti-CD20 monoclonal antibodies.
Sanofi-aventis China is a division of the world’s third-largest pharmaceutical company in global prescription sales. Under the terms of the agreement, MMR’s antibody assets may be used in the development of future treatment options for various autoimmune and B-Cell mediated diseases, including, but not limited to, lupus nephritis, systemic lupus erythematosus, psoriasis, respiratory distress syndrome, chronic lymphocytic leukemia and multiple sclerosis.
Robert H. Lorsch, chairman and chief executive officer of MMR Information Systems, Inc., stated, “Our primary business is the development, marketing and sales of the company’s personal and professional health IT products, however, maximizing shareholder value is always a primary focus.” Mr. Lorsch continued, “It now appears that monetizing pre-merger assets such as the anti-CD20 antibodies and licensing the use of clinical trials data and patient samples from FavId® trials, may represent a unique opportunity to generate shareholder value that was not contemplated as part of the company’s original post-merger business plan, particularly in the area of cancer research.”
In addition, MMR signed an agreement earlier this month with the Lymphoma Research Foundation (LRF) where the two organizations will collaborate in good faith regarding the use of pre-merger Favrille intellectual property. This research will include more than 150 lymphoma tumor samples accumulated by the company and $140 million investment on the development of the FavId vaccine.